Previous 10 | Next 10 |
VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER PR Newswire WASHINGTON , Sept. 7, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the notice ...
Vanda Pharmaceuticals Inc. (VNDA) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Mihael H. Polymeropoulos - President & Chief Executive Officer Kevin Moran - Senior Vice President & Chief Financial Officer Conference C...
Vanda Pharmaceuticals press release ( NASDAQ: VNDA ): Q2 GAAP EPS of $0.05. Revenue of $64.39M. Guidance: Total revenues $240 to $280 million. Consensus Revenue Estimate for 2022 is $265.10M For further details see: Vanda Pharmaceuticals GAAP E...
Vanda Pharmaceuticals ( NASDAQ: VNDA ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close. The consensus EPS Estimate is $0.12 (-29.4% Y/Y) and the consensus Revenue Estimate is $67M (-1.3% Y/Y). Over the last 3 months, EPS estima...
Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022 PR Newswire Conference Call and Webcast to Follow WASHINGTON , July 27, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announce...
Vanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference PR Newswire WASHINGTON , June 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate...
Vanda Pharmaceuticals Announces Presentations at SLEEP 2022 PR Newswire WASHINGTON , May 31, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2022, to be held in Charlotte, North Carolina fr...
Vanda Pharmaceuticals Announces Presentations at DDW 2022 PR Newswire WASHINGTON , May 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2022, to be held in San Diego...
I am quite impressed with Vanda Pharmaceuticals' investing thesis. Though it cooled off recently, Vanda is still positing significant revenues that I expect would leap to a higher level either next year or beyond. Despite the recent setback regarding tradipitant, Vanda has other s...
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based on its preferred valuation metric of free cash flow to enterprise value (FCF/EV) for those tr...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...